Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 26;14(5):433.
doi: 10.3390/brainsci14050433.

Combination of Two Long-Acting Antipsychotics in Schizophrenia Spectrum Disorders: A Systematic Review

Salvatore Cipolla  1 , Pierluigi Catapano  1 , Daniela D'Amico  1 , Rocchina Monda  1 , Nunzia Paola Sallusto  1 , Francesco Perris  1 , Valeria De Santis  1 , Francesco Catapano  1 , Mario Luciano  1 , Andrea Fiorillo  1
Affiliations
Review

Combination of Two Long-Acting Antipsychotics in Schizophrenia Spectrum Disorders: A Systematic Review

Salvatore Cipolla et al. Brain Sci. .

Abstract

Background: Up to 34% of patients with schizophrenia are resistant to several treatment trials. Lack of continuous and adequate treatment is associated with relapse, rehospitalization, a lower effect of antipsychotic therapy, and higher risk of side effects. Long-acting injectables antipsychotics (LAI APs) enhance compliance and improve clinical outcomes and quality of life in patients with schizophrenia, and thus it may be advisable to administer two LAI APs at the same time in cases of treatment-resistant schizophrenia. The purpose of this review is to summarize the available literature regarding the combined use of two LAI APs in patients with schizophrenia or other psychotic spectrum disorders.

Methods: An extensive literature search for relevant articles regarding any combination of two long-acting injectable antipsychotics has been performed from inception up to 9 February 2024, on PubMed, Scopus and APA PsycInfo, according to the PRISMA statement. Only studies reporting combination of two LAI APs and its clinical outcome in patients with schizophrenia and related disorders were selected.

Results: After the selection process, nine case reports, four case series and two observational retrospective studies were included in the final analysis. All patients treated with dual LAI APs reported a good response, and no new or unexpected adverse effects due to the combination of two LAIs were reported. Different drug combinations were used, and the most frequent association resulted in aripiprazole monohydrate + paliperidone palmitate once monthly (32 times).

Conclusions: Our review highlights that the treatment regimen with two concurrent LAI APs is already widely used in clinical practice and is recognized as providing a promising, effective, and relatively safe therapeutic strategy for treating the schizophrenia spectrum disorders.

Keywords: LAI; antipsychotics; clozapine; long-acting; schizophrenia; treatment-resistant.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that influenced, or could have appeared to influence, the work reported in this paper.

Figures

Figure 1
Figure 1
Flowchart of the selection process, according to PRISMA guidelines.
See this image and copyright information in PMC

References

    1. GBD 2019 Mental Disorders Collaborators Global, Regional, and National Burden of 12 Mental Disorders in 204 Countries and Territories, 1990-2019: A Systematic Analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9:137–150. doi: 10.1016/S2215-0366(21)00395-3. - DOI - PMC - PubMed
    1. Hany M., Rehman B., Azhar Y., Chapman J. StatPearls. StatPearls Publishing; St. Petersburg, FL, USA: 2024. Schizophrenia. - PubMed
    1. Charlson F.J., Ferrari A.J., Santomauro D.F., Diminic S., Stockings E., Scott J.G., McGrath J.J., Whiteford H.A. Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016. Schizophr. Bull. 2018;44:1195–1203. doi: 10.1093/schbul/sby058. - DOI - PMC - PubMed
    1. Hollis C. Youth Mental Health: Risks and Opportunities in the Digital World. World Psychiatry. 2022;21:81–82. doi: 10.1002/wps.20929. - DOI - PMC - PubMed
    1. Malla A., Boksa P., Joober R. Meeting the Challenges of the New Frontier of Youth Mental Health Care. World Psychiatry. 2022;21:78–79. doi: 10.1002/wps.20927. - DOI - PMC - PubMed

LinkOut - more resources